Department of Clinical Sciences, Lund
1291 – 1300 of 34443
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Physics for molecular radiotherapy – The battle between science and simplicity
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults with Sepsis or Septic Shock : A Systematic Review and Meta-Analysis
(
- Contribution to journal › Article
-
Mark
Recovery, Functional Status, and Health-Related Quality of Life Status up to 4 Years after First-Ever Stroke Onset : A Population-Based Study
2024) In Neuroepidemiology(
- Contribution to journal › Article
-
Mark
Mapping the Past : Geographically Linking an Early 20th Century Swedish Encyclopedia with Wikidata
2024) Joint 30th International Conference on Computational Linguistics and 14th International Conference on Language Resources and Evaluation, LREC-COLING 2024 In 2024 Joint International Conference on Computational Linguistics, Language Resources and Evaluation, LREC-COLING 2024 - Main Conference Proceedings p.11040-11048(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
(
- Contribution to journal › Article
-
Mark
A Mitochondrial Basis for Heart Failure Progression
(
- Contribution to journal › Article
-
Mark
Cutibacterium and Staphylococcus dysbiosis of the skin microbiome in acne and its decline after isotretinoin treatment
(
- Contribution to journal › Article
-
Mark
Cardiovascular risk factor assessment in late-onset seizures : A study protocol to assess the value of structured intervention
(
- Contribution to journal › Article
-
Mark
Diagnostic challenges in patients with reninomas and extrarenal renin-producing tumours
(
- Contribution to journal › Scientific review
-
Mark
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
(
- Contribution to journal › Article